These benefits are largely associated with their diuretic effects and subsequent decrease in activation of the renin-angiotensin-aldosterone system (RAAS).4 By lowering RAAS activity, SGLT-2 inhibitors help improve hemodynamic stability and reduce myocardial stress, which has led to their recommendation in clinical practice guidelines for patients with heart failure, irrespective of ejection fraction or diabetes status.5 Here, SLC5A2 is linked to heart failure.